AMTX shares are up 8.4% today, though options traders are taking a much more bearish stance. So far, 6,567 puts have crossed the tape compared to 1,605 calls, resulting in a put/c ...

Citi’s Yigal Nochomovitz trimmed his price target to $33 from $40 and kept a Buy rating following the company’s update.

Acadia Pharmaceuticals ( ACAD) sank almost 7% on Friday, closing at $20.68 after a drop of $1.50. This came after a 13% drop ...

According to The Fly, Needham lowered its price target to $35 from $41, and Deutsche Bank cut its target to $31 from $38, with both maintaining 'Buy' ratings. ・BMO Capital lowered its target to $34 ...

Acadia Pharmaceuticals ACAD announced phase III-enabling top-line results from the phase II portion of the RADIANT study ...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...

Acadia Pharmaceuticals Inc. ACAD shares lost 15% in the after-market hours on Mar 11, after the company announced the failure of its late-stage study evaluating pimavanserin for the treatment of ...

I am not optimistic about remlifanserin’s phase 3 success, with a probability of success to 25% due to efficacy and trial ...

Acadia Pharmaceuticals (ACAD) shaved more than $3 billion off its market cap Tuesday and ACAD stock plummeted after the Food and Drug Administration found deficiencies in its application for a ...